CELESTONE SOLUSPAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CELESTONE SOLUSPAN (CELESTONE SOLUSPAN).
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to inactive metabolites. |
| Excretion | Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways. |
| Half-life | Plasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection). |
| Protein binding | ~64% primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd ~0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | IM: 100% (complete absorption). Oral: not applicable (injectable only). Intra-articular: effectively 100% locally; systemic bioavailability varies. |
| Onset of Action | IM: betamethasone phosphate within 1-2 hours; betamethasone acetate within 6-12 hours. Intra-articular/soft tissue: within 12-24 hours. |
| Duration of Action | IM: 7-14 days due to acetate microcrystals providing prolonged release. Intra-articular: 7-21 days, depending on joint size and pathology. |
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal disease due to fluid retention risk. |
| Liver impairment | No specific dose adjustment for Child-Pugh categories; monitor for increased corticosteroid effects in severe hepatic impairment. |
| Pediatric use | 0.02-0.3 mg/kg/day betamethasone equivalent intramuscularly or intralesionally, divided every 12-24 hours; duration as short as possible. |
| Geriatric use | Start at low end of dosing range; monitor for hyperglycemia, osteoporosis, and fluid retention; use minimal effective dose and duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CELESTONE SOLUSPAN (CELESTONE SOLUSPAN).
| Breastfeeding | Enters breast milk; M/P ratio 0.1-0.7 based on prednisolone data. Peak milk concentrations occur 1-2 hours after dose. AAP recommends use with caution; consider delaying breastfeeding for 4 hours after dose. No reported adverse effects in infants at maternal doses ≤20 mg/day. |
| Teratogenic Risk | First trimester: Increased risk of oral clefts (odds ratio ~1.3-3.4). Second/third trimesters: Associated with fetal adrenal suppression, intrauterine growth restriction, and premature birth. Chronic use: Risk of cataracts, osteoporosis, and hypothalamic-pituitary-adrenal axis suppression in neonate. |
■ FDA Black Box Warning
Avoid intra-articular injection into unstable joints, infected areas, or near nerves. Not for intravenous use.
| Serious Effects |
Systemic fungal infection, idiopathic thrombocytopenic purpura, hypersensitivity to corticosteroids, live virus vaccination.
| Precautions | Increased risk of infection, adrenal suppression, osteoporosis, cataracts, glaucoma, and gastrointestinal perforation. Monitor for Cushing's syndrome with prolonged use. |
| Food/Dietary | Avoid high-sodium foods to reduce fluid retention and edema. Limit potassium-rich foods if hypokalemia is a concern. Grapefruit and grapefruit juice may increase systemic corticosteroid levels; use with caution. Alcohol consumption may increase risk of gastrointestinal irritation and ulcers. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Serial fetal ultrasound for growth restriction. Assess fetal adrenal suppression with neonatal evaluation. In preterm labor, use only if benefit outweighs risk; avoid prolonged therapy. |
| Fertility Effects | May impair fertility by disrupting ovulatory cycles due to suppression of gonadotropins. Chronic use may cause iatrogenic Cushing's syndrome and hypothalamic-pituitary-adrenal axis suppression, potentially reversible upon discontinuation. |
| Clinical Pearls | CELESTONE SOLUSPAN (betamethasone sodium phosphate and betamethasone acetate) is a dual-component injectable corticosteroid. The sodium phosphate component provides rapid onset (1-3 hours) while the acetate component offers sustained release (1-2 weeks). Avoid intra-articular injection in unstable joints or infected sites. Use cautious dose tapering to avoid adrenal insufficiency. Not for IV or epidural use. Monitor for signs of infection suppression. |
| Patient Advice | Do not discontinue suddenly without medical advice. · Report any signs of infection (fever, sore throat) or unusual bruising. · Avoid live vaccines during therapy. · Notify your doctor if you have diabetes, hypertension, or history of tuberculosis. · This injection is for local effect; systemic effects may occur with repeat doses. |